



RECEIVED  
JUL 08 2003  
OFFICE OF PETITIONS

George H. Scherr, Ph.D.  
33 Monee Road  
Park Forest, Illinois 60466  
USA

Phone: (708)747-3717  
Fax: (708)747-3657  
E-mail: jir@interaccess.com

November 11, 2002

Shahnam J. Sharareh  
United States Department of Commerce  
United States Patent & Trademark Office  
Organization: TC 1600 - Bldg./Room CMI  
Washington, D.C. 20231

Application Number: 09/676/670  
Applicant: Scherr, George H.  
Art Unit: 1617  
Title: Alginate Foam Compositions  
This Application is a CIP of  
09/301,228 04/29/1999 ABN  
Examiner: Dr. Shahnam Sharareh

Dear Dr. Sharareh:

This will acknowledge with appreciation your office action dated 10/22/2002 (paper # 6) and the comments and remarks made therein are appreciated.

I withdraw claims 20-76 inclusive and have added, attached herein, claims 105 to 149 inclusive.

Where my new claims reference claims that have been allowed by the examiner (Claims 77-90), I have cited those claims in order to ensure an understanding of the relationship as expressed in my new claims 105 to 149.

I believe that the new claims appended hereto overcome the objections of the examiner.

Very truly yours,

George H. Scherr, Ph.D.

GHS/jj



#11

November 11, 2002

Application Number: 09/676/670

Applicant: Scherr, George H.

Art Unit: 1617

Title: Alginate Foam Compositions

This Application is a CIP of

09/301,228 04/29/1999 ABN

Examiner: Dr. Shahnam Sharareh

**Claims 105-149**

105. The process of claim 77 in which the composition of (V) is sterilized.

106. The process of claim 105 in which the medicinal agent is a suspension of viable cells added to the sterilized composite mixture.

107. The process of claim 106 in which the composite mixture is poured onto a fibrous cloth contained in or on a tray, which fibrous cloth will become affixed to the alginate composition after the aqueous component of said composite mixture has evaporated.

108. The process of claim 106 in which the viable cells are mast cells.

109. The composition of claim 106 in which the viable cells are skin tissue cells.

110. The process of claim 109 wherein the effervescent compound is selected from a group consisting of the alkali metal carbonates.

111. The process of claim 110 wherein said effervescent compound is sodium carbonate.

112. The process of claim 106 wherein said effervescent compound is sodium bicarbonate.

113. The process of 106 wherein said water soluble acid is selected from the group consisting of acetic, lactic, malic, gluconic, hydrochloric, and ascorbic acids.

114. The process of claim 107 in which the fibrous cloth is selected from cloths prepared from cotton, polyester, wool, nylon, rayon, or mixtures thereof.

115. The process of claim 106 wherein said water-soluble alginate is selected from a group consisting of ammonium, magnesium, potassium, sodium salts of alginate, or mixtures thereof.

116. The process of claim 106 wherein said di- or trivalent cation is selected from a metal ion derived from salts selected from the group consisting of alkaline earth metal salts, alkali metal salts, transition metal salts, and mixtures thereof.

117. The process of claim 106 wherein said metal cation is selected from the group consisting of calcium, barium, copper, magnesium, iron, zinc, aluminum, manganese, silver, strontium, and mixtures thereof.

118. The process of claim 106 wherein said medicament is selected from the group consisting of collagen, maltodextrin, antibiotics, antibacterial agents, anti-inflammatory agents, ascorbic acid, amino acids, and mixtures thereof. ✓ 8B

119. The process of claim 106 wherein said plasticizer is selected from a group consisting of glycerin, propylene glycol, ethylene glycol, and polyethylene glycol or mixtures thereof.

120. The process of claim 106 wherein said surface active agent is selected from a group consisting of polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monopalmitate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan trioleate, polyoxyethylene-polyoxypropylene block polymer, or a mixture thereof.

121. The process of claim 106 wherein the di-or trivalent cation metal salt complexing the water soluble alginate is calcium sulphate.

122. The process of claim 106 wherein the di-or trivalent cation metal salt complexing the water soluble alginate is calcium chloride.

123. The process of claim 106 wherein the di-or trivalent cation metal salt complexing the water soluble alginate is calcium acetate.

124. A water-insoluble alginate sponge or foam wound dressing containing viable cells.

125. A water-insoluble alginate sponge or foam wound dressing containing a medicinal agent.

126. A water-insoluble calcium alginate sponge or foam wound dressing containing a medicinal agent.

127. A water-insoluble barium alginate sponge or foam wound dressing containing a medicinal agent.

128. A water-insoluble copper alginate sponge or foam wound dressing containing a medicinal agent.

129. A water-insoluble magnesium alginate sponge or foam wound dressing containing a medicinal agent.

130. A water-insoluble iron alginate sponge or foam wound dressing containing a medicinal agent.

131. A water-insoluble zinc alginate sponge or foam wound dressing containing a medicinal agent.

132. A water-insoluble aluminum alginate sponge or foam wound dressing containing a medicinal agent.

133. A water-insoluble manganese alginate sponge or foam wound dressing containing a medicinal agent.

134. A water-insoluble silver alginate sponge or foam wound dressing containing a medicinal agent.

135. A water-insoluble strontium alginate sponge or foam wound dressing containing a medicinal agent.

136. A water-insoluble calcium alginate sponge or foam wound dressing containing collagen.

137. A water-insoluble calcium alginate sponge or foam wound dressing containing maltodextrin.

138. A water-insoluble calcium alginate sponge or foam wound dressing containing antibiotics.

139. A water-insoluble calcium alginate sponge or foam wound dressing containing an antibacterial agent.

140. A water-insoluble calcium alginate sponge or foam wound dressing containing anti-inflammatory agents.

141. A water-insoluble calcium alginate sponge or foam wound dressing containing ascorbic acid.

142. A water-insoluble calcium alginate sponge or foam wound dressing containing amino acids.

143. A water-insoluble silver alginate sponge or foam wound dressing containing collagen.

144. A water-insoluble silver alginate sponge or foam wound dressing containing maltodextrin.


145. A water-insoluble silver alginate sponge or foam wound dressing containing antibiotics.

146. A water-insoluble silver alginate sponge or foam wound dressing containing antibacterial agents.

147. A water-insoluble silver alginate sponge or foam wound dressing containing anti-inflammatory agents.

148. A water-insoluble silver alginate sponge or foam wound dressing containing ascorbic acid.

149. A water-insoluble silver alginate sponge or foam wound dressing containing amino acids.



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

| APPLICATION NUMBER | FILING DATE | GRP ART UNIT | FIL FEE REC'D | ATTY. DOCKET NO. | DRAWINGS | TOT CLAIMS | IND CLAIMS |
|--------------------|-------------|--------------|---------------|------------------|----------|------------|------------|
| ✓ 09/676,670       | 10/02/2000  | 1615         | 661           |                  |          | 54         | 3          |

George H Scherr Ph D  
33 Monee Road  
Park Forest, IL 60466

## FILING RECEIPT



Date Mailed: 12/18/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

George H. Scherr, Park Forest, IL ;

## Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CIP OF 09/301,228 04/29/1999 ABN

## Foreign Applications

UNITED KINGDOM 9924266.1 10/13/1999

If Required, Foreign Filing License Granted 12/18/2000

\*\* SMALL ENTITY \*\*

## Title :

Aliginat foam compositions

## Preliminary Class

424

Data entry by : MARTIN, DIANE

Team : OIPE

Date: 12/18/2000

**RECEIVED**

NOV 06 2000

**OFFICE OF PETITIONS**